The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
Bharat Biotech has been submitting data to the WHO on a rolling basis and submitted additional information at WHO’s request on September 27th 2021
ABB Drives play a key role in the cleanroom infrastructure of Bharat Biotech, India’s first indigenous Covid-19 vaccine manufacturer. The drives are easy to commission, use and ensure higher energy efficiency
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021
It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
CDSCO to fast-track trials and approval for COVID19 vaccine
Subscribe To Our Newsletter & Stay Updated
